Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin plus rituximab and bendamustine versus rituximab and bendamustine in relapsed or refractory CD30-positive diffuse large B-cell lymphoma
2015-001671-51Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) comparing Brentuximab vedotin + rituximab + bendamustine with Rituximab + bendamustine (2 arms). Primary endpoint: Objective response rate. Started Aug 2015; status: completed.
02
Drugs
brentuximab vedotinrituximabbendamustine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2015-001671-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001671-51.